Speaker 1: Bloomberg Audio Studios, podcasts, radio News.
Speaker 2: The Stock Movers Report, your roundup of companies making moves
Speaker 2: in the stock market, harnessing the power of Bloomberg Data.
Speaker 3: Time to take a look at some of the stocks
Speaker 3: on the move today. We're joined by Bloomberg's Isabelle Lee.
Speaker 3: It's a normal trading day today in the New York
Speaker 3: Stock Exchange, right.
Speaker 1: Absolutely, yes, normal, But the London Stock Market is closed,
Speaker 1: so it's very quiet out there for boxing for the
Speaker 1: whole world. Yes, boxing day.
Speaker 3: Okay, that's quiet.
Speaker 1: For the whole world.
Speaker 3: Let's start with one of our favorite stocks here because
Speaker 3: it's always the most active, in Vidia in the pre market.
Speaker 1: In Vidia, Yes, this is a favorite. It's the world's
Speaker 1: largest company. It's higher but maybe five one percent in
Speaker 1: pre market trading. So they agreed to a licensing deal
Speaker 1: with AI startup GROX. So this furthers and vidious investments
Speaker 1: and companies connected to the AI boom. So the chip maker,
Speaker 1: as we know, has paid for the right to use
Speaker 1: GROS technology and will integrate its hip design into future products.
Speaker 1: So some of the startups executives are leaving to join
Speaker 1: in video to help with that effort. GROK will continue
Speaker 1: us an independent company, but they will name a new CEO.
Speaker 1: So in Vida's technology, as we know, already dominates data
Speaker 1: centers and the popularity of their offerings really has just
Speaker 1: made in Video the richest company in the chip industry.
Speaker 1: So In Video said it will use some of that
Speaker 1: cash to religious advance their uptake of AI across the economy.
Speaker 1: So why Grock Because Grock has slow latency chips and
Speaker 1: are extremely responsive to inputs. I'm going to pretend that
Speaker 1: I really understand it.
Speaker 3: Yes, okay, you'll explain that to me some other time.
Speaker 3: I've never heard of this company. Is it Citus or
Speaker 3: Citus Space?
Speaker 1: I thought it was Citus and then I listened to
Speaker 1: a video and it said Cidus when the video was
Speaker 1: introducing the CEO. So take cars, sid you it's up
Speaker 1: eight ten to one percent. This is a space and
Speaker 1: defense technology company developments there there recently announced plans to
Speaker 1: offer to sell shares if they're common class A common
Speaker 1: stock in a proposed public offering at one dollars and
Speaker 1: thirty cents a share, So they will use that for
Speaker 1: sales and marketing, operational cost, product development, et cetera. Think
Speaker 1: equities acting as a sole placement agent for the offering,
Speaker 1: and last week the company was named a contract awarding
Speaker 1: on the Missile Defense Agency's Shield IDQ program. I also
Speaker 1: had to look that up and I got into a
Speaker 1: rabbit hole into the Defense Department's website. Basically, that's a
Speaker 1: one hundred and fifty one billion dollars sealing contract. Focus
Speaker 1: on just really delivering innovative defensive capabilities to efforts that
Speaker 1: are militaristic. You could just think of it like that.
Speaker 1: So the stock has rallied though, around two hundred percent
Speaker 1: in the past month.
Speaker 3: All right, let's end up with bio Biohaven shares ticker
Speaker 3: symbol bh V, and what do they do.
Speaker 1: Bioheavens shares job fourteen percent. They're in the healthcare industry.
Speaker 1: So shares are slumping because a mid stage study of
Speaker 1: the company's experimental drug for the treatment of major depressive
Speaker 1: disorder missed the primary endpoint. So City said that data
Speaker 1: was disappointing. They had a by rating, but investors had
Speaker 1: quote very low expectations of the study working. Raymond James,
Speaker 1: who also had a by rating, said that investors they
Speaker 1: focused on the focal epilepsy opportunity and RBC said that
Speaker 1: the trial miss could be a clearing event, so to speak.
Speaker 1: So the company does not plan on additional psychiat clinical
Speaker 1: trials and will, in said, focus on obesity, immunology and
Speaker 1: epilepsy in twenty twenty six.
Speaker 3: So does everybody want to venture a guess as to
Speaker 3: what trading volume is going to be like today? We
Speaker 3: should like to put that out there.
Speaker 1: There will be ten people on Wall Street.
Speaker 2: The stock mover's report from Bloomberg Radio. Check back with
Speaker 2: us throughout the day for the latest roundup of companies
Speaker 2: making news on Wall Street and for the latest market
Speaker 2: moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube,
Speaker 2: Bloomberg dot com, and on Applecarplay and Android Auto with
Speaker 2: the Bloomberg Business app.